3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide has been researched along with levodopa in 1 studies
| Studies (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Trials (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Recent Studies (post-2010) (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Studies (levodopa) | Trials (levodopa) | Recent Studies (post-2010) (levodopa) |
|---|---|---|---|---|---|
| 14 | 0 | 6 | 17,774 | 1,900 | 4,946 |
| Protein | Taxonomy | 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide (IC50) | levodopa (IC50) |
|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | 0.5939 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 0.5939 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 2.88 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 3.729 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.146 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.258 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barlas, C; Chugh, A; Johnson, RL; Marcotte, ER; Mishra, RK; Whan, D | 1 |
1 other study(ies) available for 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide and levodopa
| Article | Year |
|---|---|
Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG).
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Brain; Dopamine; Dopamine Agonists; Drug Synergism; Levodopa; Male; MSH Release-Inhibiting Hormone; Oxidopamine; Pyrrolidinones; Quinpirole; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 1997 |